Inside Peptides
Search
Menu

Neuropeptides & Central Nervous System Signaling

Neuropeptides are endogenous peptide neurotransmitters and synthetic neuromodulators that orchestrate synaptic transmission, neurotrophic survival, circadian rhythms, and neuroinflammation. Overcoming the blood-brain barrier remains the central pharmacological challenge.

Diagram of synaptic neuropeptide transmission, TrkB receptor activation, and neurotrophic factor cascades
Neuropeptides modulate neurotransmitter release, BDNF expression, and ischemic neuroprotection.

Field Summary & Status

Early Human Evidence
Field Maturity Moderate / Regional Approvals
Primary Receptors TrkB, GABA-A modulatory sites, OTR, MC4R, Orexin-R
Target Tissues Hippocampus, Prefrontal Cortex, Hypothalamus, Brainstem, Striatum
Key Approved Medicines Oxytocin (Pitocin), Desmopressin (DDAVP)
Lead Investigational Classes Semax (ACTH 4-7 analogue), Selank (Tuftsin analogue)
Last Updated 2026-10-06

Neurochemical Modulators & Synaptic Plasticity

Neuropeptides represent one of the most chemically diverse classes of signaling molecules in the central and peripheral nervous systems. Unlike classical small-molecule neurotransmitters (such as glutamate or GABA) which are synthesized in axon terminals and stored in small clear synaptic vesicles, neuropeptides are synthesized as prohormones in neuronal cell bodies and packaged into large dense-core vesicles (LDCVs).

Neuropeptides act predominantly as slow, neuromodulatory signals that tune neural circuit excitability, promote dendritic arborization, and regulate behavioral states such as anxiety, bonding, appetite, and wakefulness.

Clinical translation in Western medicine is severely bottlenecked by the blood-brain barrier (BBB). While compounds like Semax and Selank gained regulatory registration in Russia via intranasal delivery, Western regulatory agencies require confirmatory double-blind Phase 3 trials before granting approval.

Biological Systems & Signaling Mechanisms

Central neuropeptide signaling operates through specialized neurotrophic and allosteric receptor interactions.

Detailed biological signaling pathway schematic for Neuropeptides & Central Nervous System Signaling
Integrated biological signaling pathways and physiological mechanisms in Neuropeptides & Central Nervous System Signaling.

TrkB / BDNF Neurotrophic Cascade

Upregulation of brain-derived neurotrophic factor (BDNF) mRNA and receptor tyrosine kinase B (TrkB) activation promotes neuronal survival.

Evidence Domain: Preclinical Model

Allosteric GABAergic Modulation

Modulation of GABA-A receptor sensitivity enhances inhibitory neurotransmission without classical benzodiazepine sedation.

Evidence Domain: Electrophysiology

Enzymatic Peptidase Inhibition

Stabilizing sequences (Pro-Gly-Pro tails) delay cleavage of endogenous enkephalins and neuropeptides by brain membrane peptidases.

Evidence Domain: Biochemistry

Peptide Classes & Molecular Targets

Neuropeptides span endogenous neurohypophysial hormones, ACTH analogues, and tuftsin-derived peptides.

ACTH-Derived Neurotrophic Analogues

Target: Semax
Approved in Russian Stroke Guidelines
Classification Endogenous / Synthetic
Clinical Standing Approved in Russian Stroke Guidelines
Physiological & Pharmacological Action:

Heptapeptides based on ACTH(4-7) with C-terminal stabilization designed to induce neuroprotection.

Key Representative Agents: Semax

Tuftsin-Derived Anxiolytics

Target: Selank (TP-7)
Approved in Russian Anxiety Guidelines
Classification Endogenous / Synthetic
Clinical Standing Approved in Russian Anxiety Guidelines
Physiological & Pharmacological Action:

Peptides derived from the immunomodulatory tetrapeptide tuftsin engineered for GABAergic modulation.

Key Representative Agents: Selank (TP-7)

Neurohypophysial Nonapeptides

Target: Oxytocin, Vasopressin
FDA-Approved Medicines
Classification Endogenous / Synthetic
Clinical Standing FDA-Approved Medicines
Physiological & Pharmacological Action:

Endogenous nonapeptides governing social cognition, uterine tone, and osmoregulation.

Key Representative Agents: Oxytocin, Vasopressin

Human Clinical Trials & Observational Data

Clinical investigations focus on acute stroke neuroprotection, cognitive impairment, and generalized anxiety.

Trial / Study Identifier / Compound Phase & Cohort Status / Duration Primary Findings
Semax at Different Stages of Ischemic Stroke Rehabilitation
Semax at Different Stages of Ischemic Stroke Rehabilitation
RU-CT2018 		Controlled clinical study (Semax vs no Semax subgroups)
110 patients after ischemic stroke, in early or late rehabilitation
 Completed Semax subgroups showed higher plasma BDNF levels and faster, better recovery on the Barthel index; effects on paresis were smaller.
Published 2018
Selank vs Medazepam in Generalized Anxiety
Selank vs Medazepam in Generalized Anxiety
RU-CT2008 		Active-comparator clinical study
62 patients with generalized anxiety disorder or neurasthenia (30 selank, 32 medazepam)
 Completed Anxiolytic effects of selank and medazepam were similar on Hamilton, Zung and CGI scales; selank also showed antiasthenic and psychostimulant effects.
Published 2008

Approved Medicines vs. Investigational Compounds

Clear distinction between regulatory-approved prescription medicines and experimental candidates undergoing laboratory or early clinical testing.

Compound Target / Mechanism Regulatory Status Indications / Focus Sponsor / Developer
Oxytocin (Pitocin) Approved Biological Target FDA/EMA Approved (1955) Labor Induction & PPH Multiple Manufacturers
Desmopressin (DDAVP) Approved Biological Target FDA/EMA Approved (1978) Diabetes Insipidus & Nocturnal Enuresis Ferring
Semax BDNF upregulation & ischemic neuroprotection Russian Approved / Western Unapproved Preclinical / Investigational Peptogen
Selank GABA-A allosteric modulation Russian Approved / Western Unapproved Preclinical / Investigational Peptogen

Safety Considerations & Blood-Brain Transport Risks

Modulating central neurotransmission requires careful evaluation of psychiatric tolerability and nasal mucosa integrity.

Central Nervous System Tolerability

Mild to Moderate

Transient headache, sleep disturbances, and paradoxical agitation reported with unmonitored neuropeptide dosing.

Lack of Western Regulatory Oversight

Moderate to High

Imported or gray-market neuropeptide solutions lack audited sterility testing and HPLC characterization.

Unresolved Scientific Questions

Key mechanistic and translational questions currently under active scientific investigation.

How much intact peptide crosses the human blood-brain barrier via nasal delivery?

Quantitative human PET radiotracer studies demonstrating direct olfactory-to-brain uptake remain sparse.

Can Russian clinical trial results be reproduced in double-blind Western Phase 3 trials?

Confirmatory multi-center Western trials using modern placebo-controlled protocols have not been completed.

Evolution of Research & Milestones

Historical scientific breakthroughs, isolation events, structural discoveries, and regulatory milestones.

1953

Oxytocin Synthesized

Du Vigneaud completes synthesis of the first neuropeptide hormone.

1982

Semax Engineered

Russian Academy of Sciences synthesizes ACTH(4-7)-PGP.

2026

Current Status

Neuropeptides remain under evaluation for traumatic brain injury and neurodegeneration.

Scientific References

Primary scientific publications, randomized controlled trials, and clinical consensus papers referenced in this field overview.

  1. The efficacy of semax in the treatment of patients at different stages of ischemic stroke Gusev EI et al. Zh Nevrol Psikhiatr Im S S Korsakova 2018. Zh Nevrol Psikhiatr · 2018
    Source
  2. Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia Zozulia AA et al. Zh Nevrol Psikhiatr Im S S Korsakova 2008. Zh Nevrol Psikhiatr · 2008
    Source
  3. Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus Dolotov OV et al. Brain Res 2006. Brain Res · 2006
    Source

Scientific & Educational Disclaimer

InsidePeptides.org provides scientific and educational analysis of peer-reviewed research for informational purposes only. This overview does not constitute medical advice, diagnosis, treatment, prescription, or clinical guidance. Incretin and metabolic peptide medicines require physician oversight, prescription authorization, and regular clinical monitoring. Never adjust, initiate, or discontinue prescribed treatments without direct consultation with a qualified medical specialist.